Effect of Edirex-Sanovel (pioglitazone) medication on the incidence of dementia

Vera Kapetivadze¹, R. Tabukashvili¹, N. Gegeshidze¹, Kh. Tchaava¹, T. Lazashvili¹, Z. Magapheridze¹, and Z. Grigorashvili¹

1Department of Internal Medicine, Tbilisi State Medical University, Georgia
Correspondence: verakap@rambler.ru

Abstract

Objective: Peroxisome proliferator activated receptor γ-activating drugs show various salutary effects in preclinical models of neurodegenerative disease. The decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-oriented data sources.

Methods: Using observational data from 2012-2015, we analyzed the association of Edirex-Sanovel (pioglitazone) and incidence of dementia in a prospective cohort study of 45 subjects aged ≥60 years who, at baseline, were free of dementia and insulin-dependent diabetes mellitus. We distinguished between nondiabetics, diabetics without Edirex-Sanovel, diabetics with prescriptions of 6 calendar quarters of Edirex-Sanovel, and diabetics with ≥6 quarters. Cox proportional hazard models explored the relative risk (RR) of dementia incidence dependent on edirex-sanovel use adjusted for sex, age, use of rosiglitazone or metformin, and cardiovascular comorbidities.

Results: Long-term use of pioglitazone was associated with a lower dementia incidence. Relative to nondiabetics, the cumulative long-term use of Edirex-Sanovel reduced the dementia risk by 49% (RR = 0.50, p = 0.027). If diabetes patients used Edirex-Sanovel 6 quarters, the dementia risk was comparable to those of nondiabetics (RR = 1.20, p = 0.36), and diabetes patients without a Edirex-Sanovel treatment had a 25% increase in dementia risk (RR = 1.27, p < 0.001). We did not find evidence for age effects, nor for selection into Edirex-Sanovel treatment due to obesity.

Interpretation: These findings indicate that Edirex-Sanovel treatment is associated with a reduced dementia risk in initially non-insulin-dependent diabetes mellitus patients. Prospective clinical trials are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.